Long-term Testis Cancer Survivors in Canada-Mortality Risks in a Large Population-based Cohort
- PMID: 34337478
- PMCID: PMC8317812
- DOI: 10.1016/j.euros.2020.10.005
Long-term Testis Cancer Survivors in Canada-Mortality Risks in a Large Population-based Cohort
Abstract
Background: Testis cancer (TC) patients are young with excellent cancer prognosis. Hence, the risk of late-onset treatment-related morbidity and mortality is of concern due to longer survival after treatment.
Objective: We set to characterize long-term survival of TC patients through a Canadian population dataset.
Design setting and participants: We used a population-based dataset, the Canadian Census Health and Environment Cohort (CanCHEC), to identify individuals diagnosed with TC between 1991 and 2010. We compared them with all other male individuals without TC.
Outcome measurements and statistical analysis: The primary outcome was mortality due to cardiovascular disease (CVD) or nontesticular malignancy. Mann-Whitney or chi-square test was used where applicable. Data were analyzed using a Cox proportional hazard model with and without matching.
Results and limitations: We identified 1950 individuals with TC. We compared them with 1 300 295 men with no TC. There were 335 deaths in the study group during the study period (17.2%) with a mean follow-up of 19.6 yr. TC patients were at increased risk of death from secondary malignancies (hazard ratio [HR] 1.63, 95% confidence interval [CI] 1.39-1.91; p < 0.0001) with specific risks for hematologic neoplasms (HR 3.86, 95% CI 2.78-5.37; p < 0.001) and other malignancies (HR 2.41, 95% CI 1.76-3.29; p < 0.001). Gastrointestinal, hematologic, and respiratory toxicities were the most common secondary malignancies leading to death. When stratified according to histology, nonseminoma (NS) patients were at significantly increased risk of death from CVD (HR 2.03, 95% CI 1.27-3.25; p = 0.0032). Individuals with seminoma were at increased risk of death from other nontestis neoplasms (HR 1.46, 95% CI 1.17-1.82; p = 0.0007), specifically hematologic neoplasms (HR 2.09, 95% CI 1.18-3.72; p = 0.0118).
Conclusions: NS patients are at increased risk of CVD-related death, whereas seminoma patients are at increased risk of death from non-testis-related malignancies.
Patient summary: We report long-term mortality following diagnosis of testis cancer. Nonseminoma patients have an increased risk of death from cardiovascular disease, while seminoma patients have an increased risk of death from secondary malignancies.
Keywords: Secondary neoplasm; Survivorship; Testicular neoplasm.
Crown Copyright © 2020 Published by Elsevier B.V. on behalf of European Association of Urology.
Similar articles
-
Mortality-Air Pollution Associations in Low Exposure Environments (MAPLE): Phase 2.Res Rep Health Eff Inst. 2022 Jul;2022(212):1-91. Res Rep Health Eff Inst. 2022. PMID: 36224709 Free PMC article.
-
Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study.J Clin Oncol. 2015 Oct 1;33(28):3105-15. doi: 10.1200/JCO.2014.60.3654. Epub 2015 Aug 3. J Clin Oncol. 2015. PMID: 26240226 Free PMC article.
-
Mortality and Morbidity Effects of Long-Term Exposure to Low-Level PM2.5, BC, NO2, and O3: An Analysis of European Cohorts in the ELAPSE Project.Res Rep Health Eff Inst. 2021 Sep;2021(208):1-127. Res Rep Health Eff Inst. 2021. PMID: 36106702 Free PMC article.
-
Actual causes of death in thyroid cancer patients in Korea: A Nationwide Case Control Cohort Study.Eur J Endocrinol. 2020 Jan;182(1):103-110. doi: 10.1530/EJE-19-0548. Eur J Endocrinol. 2020. PMID: 31721722
-
Exploring the spectrum of late effects following radical orchidectomy for stage I testicular seminoma: a systematic review of the literature.Support Care Cancer. 2019 Feb;27(2):373-382. doi: 10.1007/s00520-018-4492-7. Epub 2018 Oct 22. Support Care Cancer. 2019. PMID: 30350189
Cited by
-
Associations between cancer survivorship and subsequent respiratory disease: a systematic literature review.BMJ Open Respir Res. 2025 Jun 4;12(1):e002681. doi: 10.1136/bmjresp-2024-002681. BMJ Open Respir Res. 2025. PMID: 40473269 Free PMC article.
-
Cardio-oncology rehabilitation and exercise: evidence, priorities, and research standards from the ICOS-CORE working group.Eur Heart J. 2025 Aug 1;46(29):2847-2865. doi: 10.1093/eurheartj/ehaf100. Eur Heart J. 2025. PMID: 40036781 Free PMC article. Review.
-
Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors.Eur Urol Open Sci. 2022 Apr 27;40:46-53. doi: 10.1016/j.euros.2022.03.010. eCollection 2022 Jun. Eur Urol Open Sci. 2022. PMID: 35638085 Free PMC article.
-
Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the Retroperitoneum.J Urol. 2024 Jan;211(1):80-89. doi: 10.1097/JU.0000000000003697. Epub 2023 Sep 6. J Urol. 2024. PMID: 37672753 Free PMC article.
References
-
- Canadian Cancer Society . 2019. Canadian cancer statistics.
-
- Hanna N., Einhorn L.H. Testicular cancer: a reflection on 50 years of discovery. J Clin Oncol. 2014;32:3085–3092. - PubMed
-
- Verdecchia A., Francisci S., Brenner H. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8:784–796. - PubMed
-
- International Germ Cell Cancer Collaborative Group International Germ Cell Consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15:594–603. - PubMed
-
- Subramanian V.S., Nguyen C.T., Stephenson A.J., Klein E.A. Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. Urol Oncol Semin Orig Investig. 2010;28:504–509. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous